SELECTIVE SEROTONIN-REUPTAKE INHIBITORS AND INCREASED RISK OF PERSISTENT PULMONARY HYPERTENSION
S elective serotonin-reuptake inhibitors (SSRIs) taken late in pregnancy are associated with development of persistent pulmonary hypertension in the newborn (PPHN), according to the results of a study published in The New England Journal of Medicine. Using a case-control design, the investigators 1 found that neonates born to mothers who took SSRIs during the latter half of pregnancy had a much higher risk of developing PPHN than those whose mothers did not take SSRIs or took them only during the first half of pregnancy. Although this retrospective study does not establish causality, several plausible causal mechanisms were proposed. 1 Selective serotonin-reuptake inhibitors can accumulate in the lungs, increase pulmonary vascular resistance and proliferation of smooth muscle cells, and inhibit nitric oxide synthesis. This is not the first study to link SSRI use in pregnancy with PPHN. A previous cohort study suggested a possible association between maternal use of the SSRI fluoxetine late in the third trimester of pregnancy and the risk of PPHN in the infant. 2 Clinicians and patients must consider all available evidence in deciding whether the risks associated with exposure to SSRI outweigh the benefits of the therapy. 3
REVISED ROP SCREENING GUIDELINES ISSUED
R etinopathy of prematurity (ROP) is a serious disorder unique to the immature retinal tissue of the very low birth weight preterm infant. 1 Poor visual outcomes can be reduced with prompt diagnosis and treatment with peripheral retinal cryotherapy and retinal ablation using laser photocoagulation. 1 Recently, the American Academy of Pediatrics has issued revised guidelines for both initial and follow-up ophthalmologic examinations for detecting changes suggestive of ROP before they become permanently destructive. 1 The initiation of acute-phase ROP screening should be based on the infant's postmenstrual age (gestational age at birth plus chronological age). The guidelines provide a table to determine when to first screen infants born at 22 to 32 weeks. Reexaminations are recommended by the examining ophthalmologist on the basis of retinal findings, according to the international classification. The guidelines also discuss considerations with regard to treatment, communication with parents, and delegation of responsibility for follow-up if the infant is transferred or discharged. 1 
WEB-BASED BILIRUBIN MANAGEMENT
T he most recent guidelines for management of hyperbilirubinemia in newborns emphasize the importance of using the infant's age in hours, rather than days, when making decisions regarding treatment and follow-up. BiliTool is a web-based bilirubin management guide that integrates both the hourspecific bilirubin nomogram for hyperbilirubinemia risk stratification and the phototherapy guidelines from the 2004 American Academy of Pediatrics (AAP) guidelines for management of hyperbilirubinemia in newborn infants of 35 or more weeks of gestation. 1 When the user enters a bilirubin value and an infant's age in hours at the time of blood draw, BiliTool returns a risk zone and the AAP phototherapy recommendation. At the BiliTool website, 2 users can also download a version for handheld computers.
BiliTool was developed by Tony Burgos, MD, MPH, and Chris Longhurst, MD, MS, of Stanford University School of Medicine and Stuart Turner, DVM, MS, of the University of California. BiliTool Palm was developed by Randy Young, MD, Lucile Packard Children's Hospital.
